Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis
(Posted by Tom Lamb at Drug Injury Watch)
In late January 2024, a leading medical journal for ophthalmologists and retina specialists, the Journal
Drug Injury Watch
Blog Authors
Latest from Drug Injury Watch
"New" Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes
(Posted by Tom Lamb at Drug Injury Watch)
Semaglutide-containing drugs that are being used for weight loss purposes…
Gastroparesis Case Reports Involving the Use of GLP-1 Receptor Agonists Semaglutide and Dulaglutide
Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity
(Posted by Tom Lamb at Drug Injury Watch)
In this article, we present some gastroparesis case reports involving the…
Prolia Increased Risk Of Hypocalcemia In Patients With Chronic Kidney Disease (CKD) Can Be 20-Times Higher Than Pills
Prolia “Black Box” Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events To Death
(Posted by Tom Lamb at Drug Injury Watch)
A January 2024 JAMA Original Investigation article, “Severe Hypocalcemia With Denosumab Among…
Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed
December 2023 JAMA Ophthalmology Viewpoint Piece About Syfovre Calls for Independent and Unbiased Evaluation
(Posted by Tom Lamb at Drug Injury Watch)
UPDATE: From this February 28, 2024, Fierce Pharma news report, “Apellis cites current challenges with Syfovre…
Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss
(Posted by Tom Lamb at Drug Injury Watch)
UPDATE: From this February 28, 2024, Fierce Pharma news report, “Apellis cites current…
Syfovre Patients Eye Side Effects Cases at Iowa Clinic: Important 2023 AAO Meeting Presentation
A Syfovre Case of Hemorrhagic Occlusive Vasculitis-type Inflammation With Continued Blindness Is Reported
(Posted by Tom Lamb at Drug Injury Watch)
UPDATE: From this February 28, 2024, Fierce Pharma news report, “Apellis cites current challenges with Syfovre…
Ozempic, Wegovy, Other GLP-1 Semaglutide Weight-Loss Drugs Linked to Gastroparesis in Recent Medical Study
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients
(Posted by Tom Lamb at Drug Injury Watch)
An October 2023 medical journal article presented the results of a recent…
Apellis Updates Number of Syfovre Retinal Vasculitis Cases But Provides No Further "Explanation"
On That Aspect, in August 2023 Apellis Asked Doctors to Stop Using Syfovre Injection Kits With a 19-gauge Filter Needle
(Posted by Tom Lamb at Drug Injury Watch)
UPDATE: From this February 28, 2024, Fierce Pharma news report,…
Ozempic: Reports of Gastrointestinal Disorder Ileus Added to Drug Label in September 2023
Paralytic Ileus, the Slowing of Food Movement Through Digestive System, is Similar to Intestinal Obstruction
(Posted by Tom Lamb at Drug Injury Watch)
In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and…